Helix BioPharma (TSE:HBP) Sets New 1-Year Low – Here’s Why

Helix BioPharma Corp. (TSE:HBP) hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as C$0.75 and last traded at C$0.75, with a volume of 22,051 shares changing hands. The stock had previously closed at C$0.90.

Helix BioPharma Stock Down 16.7%

The firm has a market cap of C$57.28 million, a PE ratio of -18.75 and a beta of 1.39. The business’s 50 day moving average price is C$1.17 and its 200 day moving average price is C$1.60. The company has a debt-to-equity ratio of 29.27, a current ratio of 0.19 and a quick ratio of 1.03.

Helix BioPharma (TSE:HBP) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. On average, equities research analysts expect that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

About Helix BioPharma

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA¿, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA¿, a pre-IND gemcitabine prodrug for advanced solid tumors.